Children who received Moderna COVID-19 Vaccine for primary series:

  • Children ages 6 months 4 years:  1 bivalent Moderna booster dose is recommended at least 2 months after completion of the primary series. Currently, only the bivalent Moderna booster dose is authorized for children in this age group who complete a Moderna primary series.
  • Children age 5 years: 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended at least 2 months after completion of the primary series.
  • Children ages 6- 11 years: 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended at least 2 months after completion of the primary series.

Children who received Pfizer-BioNTech COVID-19 Vaccine for primary series:

      Children ages 6 months 4 years: A bivalent vaccine is administered for the third primary series dose at least 8 weeks after the second monovalent primary series dose (children who previously received a 3-dose monovalent primary series are not authorized to repeat the third primary series dose using the bivalent Pfizer-BioNTech vaccine). Currently, a booster dose using any COVID-19 vaccine is not authorized for children in this age group who complete a 3-dose Pfizer-BioNTech primary series, regardless of which Pfizer-BioNTech vaccine (i.e., a monovalent or bivalent) was administered for the third primary series dose.

      Children age 5 years:  1 bivalent Pfizer-BioNTech booster dose is recommended. The primary series doses are separated by 3 - 8 weeks and the bivalent booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose. Currently, only the bivalent Pfizer-BioNTech booster dose is authorized for children age 5 years who complete a Pfizer-BioNTech primary series.

      Children ages 6 - 11 years: 1 bivalent mRNA booster dose (Moderna or Pfizer-BioNTech) is recommended. The primary series doses are separated by 3-8 weeks and the bivalent mRNA booster dose is administered at least 2 months after completion of the primary series (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.